Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.
Identifieur interne : 000421 ( PubMed/Corpus ); précédent : 000420; suivant : 000422Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.
Auteurs : Nobuyuki Nosaka ; Masato Yashiro ; Mutsuko Yamada ; Yosuke Fujii ; Hirokazu Tsukahara ; Keyue Liu ; Masahiro Nishibori ; Akihiro Matsukawa ; Tsuneo MorishimaSource :
- Critical care (London, England) [ 1466-609X ] ; 2015.
English descriptors
- KwdEn :
- Administration, Intravenous, Animals, Antibodies, Monoclonal (administration & dosage), Dogs, HMGB1 Protein (antagonists & inhibitors), HMGB1 Protein (immunology), Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (immunology), Madin Darby Canine Kidney Cells, Male, Mice, Mice, Inbred C57BL, Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (pathology), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (pathology), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal.
- chemical , antagonists & inhibitors : HMGB1 Protein.
- chemical , immunology : HMGB1 Protein.
- drug effects : Influenza A Virus, H1N1 Subtype.
- drug therapy : Orthomyxoviridae Infections, Pneumonia, Viral.
- immunology : Influenza A Virus, H1N1 Subtype, Orthomyxoviridae Infections, Pneumonia, Viral.
- pathology : Orthomyxoviridae Infections, Pneumonia, Viral.
- Administration, Intravenous, Animals, Dogs, Madin Darby Canine Kidney Cells, Male, Mice, Mice, Inbred C57BL, Treatment Outcome.
Abstract
Provision for the emergence of an influenza pandemic is an urgent issue. The discovery of a novel anti-influenza therapeutic approach would increase the effectiveness of traditional virus-based strategies. This study was undertaken to evaluate the therapeutic effects of anti-high mobility group box-1 (HMGB1) monoclonal antibody (mAb) treatment on influenza A virus (H1N1)-induced pneumonia in mice.
DOI: 10.1186/s13054-015-0983-9
PubMed: 26067826
Links to Exploration step
pubmed:26067826Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.</title><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. pv702xz5@s.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. yashiro@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. prqv5jku@s.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. fujii-y@cc.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. tsukah-h@cc.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Keyue" sort="Liu, Keyue" uniqKey="Liu K" first="Keyue" last="Liu">Keyue Liu</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. liukeyue@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. mbori@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name><affiliation><nlm:affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. amatsu@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. tmorishima@okayamah.rofuku.go.jp.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26067826</idno><idno type="pmid">26067826</idno><idno type="doi">10.1186/s13054-015-0983-9</idno><idno type="wicri:Area/PubMed/Corpus">000421</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000421</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.</title><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. pv702xz5@s.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. yashiro@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. prqv5jku@s.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. fujii-y@cc.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. tsukah-h@cc.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Keyue" sort="Liu, Keyue" uniqKey="Liu K" first="Keyue" last="Liu">Keyue Liu</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. liukeyue@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. mbori@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name><affiliation><nlm:affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. amatsu@md.okayama-u.ac.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. tmorishima@okayamah.rofuku.go.jp.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Critical care (London, England)</title><idno type="eISSN">1466-609X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term><term>Animals</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Dogs</term><term>HMGB1 Protein (antagonists & inhibitors)</term><term>HMGB1 Protein (immunology)</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Madin Darby Canine Kidney Cells</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (pathology)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (pathology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term><term>Animals</term><term>Dogs</term><term>Madin Darby Canine Kidney Cells</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Provision for the emergence of an influenza pandemic is an urgent issue. The discovery of a novel anti-influenza therapeutic approach would increase the effectiveness of traditional virus-based strategies. This study was undertaken to evaluate the therapeutic effects of anti-high mobility group box-1 (HMGB1) monoclonal antibody (mAb) treatment on influenza A virus (H1N1)-induced pneumonia in mice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26067826</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><PubDate><Year>2015</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.</ArticleTitle><Pagination><MedlinePgn>249</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-015-0983-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Provision for the emergence of an influenza pandemic is an urgent issue. The discovery of a novel anti-influenza therapeutic approach would increase the effectiveness of traditional virus-based strategies. This study was undertaken to evaluate the therapeutic effects of anti-high mobility group box-1 (HMGB1) monoclonal antibody (mAb) treatment on influenza A virus (H1N1)-induced pneumonia in mice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nine-week-old male C57BL/6 mice were inoculated with H1N1, then anti-HMGB1 mAb or control mAb were administered intravenously at 1, 24 and 48 hours after H1N1 inoculation and the survival rate was analyzed. Lung lavage and histopathological analysis were performed on days 3, 5, 7 and 10 after inoculation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Anti-HMGB1 mAb significantly improved the survival rate of H1N1-inoculated mice (1 out of 15 versus 8 out of 15 deaths in the anti-HMGB1 mAb-treated group versus the control mAb-treated group, p < 0.01), although the treatment did not affect virus propagation in the lungs. The treatment also significantly attenuated histological changes and neutrophil infiltration in the lungs of H1N1-inoculated mice. This was associated with inhibition of HMGB1 and suppression of inflammatory cytokine/chemokine expression and oxidative stress enhancement, which were observed in H1N1-inoculated mice. The expression of receptor for advanced glycation end products and nuclear factor κB was attenuated by the treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Anti-HMGB1 mAb may provide a novel and effective pharmacological strategy for severe influenza virus infection in humans by reducing the inflammatory responses induced by HMGB1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. pv702xz5@s.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yashiro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. yashiro@md.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Mutsuko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. prqv5jku@s.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. fujii-y@cc.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukahara</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. tsukah-h@cc.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Keyue</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. liukeyue@md.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishibori</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. mbori@md.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsukawa</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. amatsu@md.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishima</LastName><ForeName>Tsuneo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. tmorishima@okayamah.rofuku.go.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C582808">HMGB1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care. 2015;19:401</RefSource><PMID Version="1">26594030</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26067826</ArticleId><ArticleId IdType="doi">10.1186/s13054-015-0983-9</ArticleId><ArticleId IdType="pii">10.1186/s13054-015-0983-9</ArticleId><ArticleId IdType="pmc">PMC4490661</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA. 2009 Nov 4;302(17):1880-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19822626</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2013;17(6):R301</Citation><ArticleIdList><ArticleId IdType="pubmed">24373231</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2010;14(6):R203</Citation><ArticleIdList><ArticleId IdType="pubmed">21062445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2014 Dec;40:1-116</Citation><ArticleIdList><ArticleId IdType="pubmed">25010388</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1973 Dec 3;40(1):215-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4772679</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Jul 15;181(2):1454-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18606700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Sep;86(17):9122-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22696656</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Dev. 2014 Jun;36(6):484-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23907181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Physiol Biochem. 2014;34(4):1373-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25301363</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2007 Dec;220:35-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17979838</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2015 Jan 2;195:9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">25197038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 May 23;497(7450):498-502</Citation><ArticleIdList><ArticleId IdType="pubmed">23636320</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2013 Jan;41(1):171-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23222257</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Oct;83(20):10366-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19641000</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Complement Alternat Med. 2010 Dec;7(4):501-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19779008</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics Inform. 2013 Dec;11(4):224-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24465234</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1993 Sep 1;151(5):2399-408</Citation><ArticleIdList><ArticleId IdType="pubmed">8360469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2012 Nov;55(3):214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22884669</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20547845</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(6):e38214</Citation><ArticleIdList><ArticleId IdType="pubmed">22679491</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1995 Oct 27;270(43):25752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7592757</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2013 Nov;100(2):446-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24084488</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Aug 13;361(7):680-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19564631</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2009 Apr;33(4):852-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19129272</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 2014;58(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24717031</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2448-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8637894</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent Pat Endocr Metab Immune Drug Discov. 2012 Sep;6(3):201-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22845335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2011 Jan;121(1):6-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21206092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2009 Oct;48(10):1190-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19589888</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2006 Oct;12(10):1203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16964257</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Immunol. 2012 Sep;56(9):651-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22734496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Infect Dis. 2014;67(2):100-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24647251</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2000 Sep 15;165(6):2950-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10975801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2012 Sep;72(3):373-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22915134</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17):1872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncol Lett. 2014 Apr;7(4):1239-1242</Citation><ArticleIdList><ArticleId IdType="pubmed">24944700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2001 Jul;64(3):262-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11424113</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Feb 1;29(6):1135-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21115061</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16251290</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1925-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19815860</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Res Commun. 2008 Feb;32(2):137-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17846911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2014 Jan;2(1):23-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24461892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2014 Jan;14(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24239327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Med. 2014;20:138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">24531836</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1999 Jul 9;285(5425):248-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10398600</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Apr 3;370(14):1335-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24693893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine. 2011 Nov;56(2):180-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21862344</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Drug Resist. 2013 Nov 19;6:187-98</Citation><ArticleIdList><ArticleId IdType="pubmed">24277988</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2007 Dec;21(14):3904-16</Citation><ArticleIdList><ArticleId IdType="pubmed">17628015</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2009 Sep 1;391(2):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19592063</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiogenesis. 2008;11(1):91-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18264787</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000421 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000421 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26067826
|texte= Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26067826" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |